Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ARDX Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: June 19, 2026
Report Source: 2026 1st Quarter Report
Ardelyx Inc. Stock Analysis ARDX
United States Health Care Small Cap Report: Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Waltham, Massachusetts and currently employs 489 full-time employees. The company went IPO on 2014-06-19. The firm markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. NHE3 is an antiporter expressed on the apical surface of the small and large intestines. Tenapanor is a minimally absorbed, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation. Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. In addition to commercializing IBSRELA and XPHOZAH, it is also developing a next-generation NHE3 inhibitor.
Read More Ardelyx Inc (ARDX) Chart
Key Statistics of Ardelyx Inc (ARDX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$6.35Volume
3.09MP/E Ratio (TTM)
-52 Week Range
Market Cap
1.57BAvg. Volume
3.43MDividend Yield
-Financial Metrics & Statements of Ardelyx Inc (ARDX)
FAQ's for Ardelyx Inc (ARDX)
- According to Musaffa’s Shariah screening methodology, Ardelyx Inc (ARDX) is currently classified as HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Ardelyx Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Ardelyx Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Ardelyx Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Ardelyx Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Ardelyx Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.